ClosedOpportunity CDC-RFA-GH21-2160

Hospital Based Birth Defects Surveillance in Kampala, Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR)

Centers for Disease Control - CGH · Department of Health and Human Services

At a glance

Hospital Based Birth Defects Surveillance in Kampala, Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR) is a closed federal cooperative agreement opportunity from the Centers for Disease Control - CGH (Department of Health and Human Services). The application deadline was May 4, 2021. Applicant types listed as eligible include others (see notice). Cost sharing is not required. It is funded under Assistance Listing 93.067 (Global AIDS).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

Posted: Mar 4, 2021
Close date: May 4, 2021
Award floor: Not specified
Award ceiling: Not specified
Est. total funding: Not specified
Expected awards: 1
Cost sharing: Not required
Funding instrument: Cooperative Agreement
Opportunity category: Discretionary

Who can apply

Others (see notice)

Additional information on eligibility (from the notice)

Eligible applicants that can apply for this NOFO are:Makerere University-Johns Hopkins University Research Collaboration (MU-JHU)

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $1,000,000 for Year 1, subject to the availability of funds.This NOFO aims to: 1) continue a birth defects surveillance system in at least four main hospitals in Kampala, Uganda focusing on major external structural birth defects; and 2) determine if maternal use of dolutegravir, cotrimoxazole or other medications during very early pregnancy is associated with a higher risk of birth defects in newborns. Results from these activities will provide background rates of birth defects in Kampala, provide baseline estimates of maternal medication use to treat HIV in pregnancy, and ascertain any correlation between medication use and external birth defects. WHO and PEPFAR will use these findings to inform guidance regarding use of specific HIV medications during pregnancy.

Assistance Listing

What is an ALN?

93.067Global AIDSProgram →

Reported obligations under ALN 93.067

Historical data · not a prediction

FY24

$1.66B

FY25

$887M

FY26

$502M est.

Source: SAM.gov Assistance Listing 93.067. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

Centers for Disease Control - CGH
dln6@cdc.gov
770-488-2756

Quick answers

Who is eligible to apply for this opportunity?

The official notice lists these applicant types as eligible: Others (see notice). Additional restrictions may apply; review the full notice.

How do I apply for this opportunity?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity CDC-RFA-GH21-2160), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.

Closes in 8 daysALN 93.067